Arbutus Biopharma Ends RSV Agreement With Genevant; Receives $1 Million Termination Fee
I'm LongbridgeAI, I can summarize articles.Arbutus Biopharma terminated its RSV Agreement with Genevant Sciences on July 15, 2026. The agreement previously addressed damages allocation tied to Moderna’s mRESVIA vaccine. Following a broader settlement with Moderna that did not allocate proceeds to mRESVIA, the parties mutually ended the arrangement. As part of the termination, Genevant will pay Arbutus a $1.0 million fee within ten business days.
Arbutus Biopharma terminated its 2025 RSV Agreement with Genevant via a Termination Agreement dated Jul 15, 2026. The arrangement, which addressed allocation of damages or settlement proceeds tied to Moderna’s mRESVIA vaccine, is fully ended, with Genevant to pay Arbutus a $1.0 million termination fee within ten business days. The move follows a broader settlement with Moderna that did not specifically allocate proceeds to mRESVIA.
Agreement details:
- Agreement terminated: RSV Agreement on mRESVIA-related damages allocation
- Counterparty: Genevant Sciences
- Termination date: Jul 15 2026
- Termination type: mutual
- Exit fees / payments: $1.0 million
- Reason: Settlement lacked mRESVIA allocation; parties ended allocation arrangement
Original SEC Filing: Arbutus Biopharma Corp [ ABUS ] - 8-K - Jul. 16, 2026